Biology:Adegramotide
From HandWiki
Adegramotide (DSP-7888) is an experimental drug intended for treatment of various hematologic malignancies and solid tumors, including glioblastoma multiforme.[1] It is a peptide vaccine and has finished phase I clinical trials and phase II clinical trials.[2][3]
As of 14 December 2021, phase III clinical research has been cancelled due to low efficacy markers during interim review of study data for Ombipepimut-S Emulsion (DSP-7888) in combination with Bevacizumab.[4][5]
The phase III trials for DSP-7888 with checkpoint inhibitors for platinum-resistant ovarian cancer, as of 13 August 2024, is still continuing as planned.[4][6]
References
- ↑ "Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies". Targeted Oncology 16 (4): 461–469. July 2021. doi:10.1007/s11523-021-00813-6. PMID 33939067.
- ↑ Boston Biomedical (11 May 2017). A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy. U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT03149003.
- ↑ Suginobe. "Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors" (in en). https://pubchem.ncbi.nlm.nih.gov/compound/121488164.
- ↑ 4.0 4.1 Sumitomo Dainippon Pharma Oncology Inc. "Sumitomo Dainippon Pharma Oncology Provides Update on Phase 3 WIZARD 201G Study of Ombipepimut-S Emulsion (DSP-7888) in Patients with Recurrent or Progressive Glioblastoma" (in en). https://www.prnewswire.com/news-releases/sumitomo-dainippon-pharma-oncology-provides-update-on-phase-3-wizard-201g-study-of-ombipepimut-s-emulsion-dsp-7888-in-patients-with-recurrent-or-progressive-glioblastoma-301444814.html.
- ↑ "Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888 in Patients with Glioblastoma Terminates | Sumitomo Pharma" (in en). https://www.sumitomo-pharma.com/news/20211215.html.
- ↑ "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors". https://clinicaltrials.gov/study/NCT03311334.
 |  |
